GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

TransThera Sciences (Nanjing) 2617.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

8.04

-0.62%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About TransThera Sciences (Nanjing)

Its shares trade on HKEX under the ticker 2617.HK. It has been listed since 23 June 2025. In the fiscal year to 31 December 2023, it reported revenue of CN¥1.2m and a net loss of CN¥344.1m. At that date it held total assets of CN¥887.1m and shareholders' equity of CN¥783.2m.

TransThera Sciences (Nanjing), Inc. engages in the research and development of clinical biopharmaceutics. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2025-06-23. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
23 Jun 2025
Employees
121

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • TransThera Sciences employs 121 full-time staff in Nanjing.
  • The company went public on the Hong Kong Stock Exchange in 2025.
  • Tinengotinib is a core product targeting drug-resistant solid tumors.

Weaknesses

  • The firm is a small biotechnology company with limited resources.
  • Most pipeline candidates are still in clinical stages of development.
  • The company relies heavily on the success of its lead drug candidate.

Opportunities

  • The oncology pipeline includes candidates for hematologic malignancies.
  • Products may be efficacious in prostate cancer and breast cancer.
  • Research targets inflammatory diseases and chronic heart failure conditions.

Threats

  • Biopharmaceutical development carries high risks of clinical trial failure.
  • Competitors may develop superior treatments for solid tumors.
  • Regulatory approval timelines for new drugs can be unpredictable.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.